Detailed instructions for dabrafenib/dabrafenib: indications, usage and precautions

Dabrafenib, trade name TAFINLAR, is a targeted therapy drug, a kinase inhibitor , mainly used to treat malignant tumors related to BRAF gene mutations. The following will introduce its indications, usage, dosage and usage restrictions in detail to help patients better understand the drug.

1. Indications

1. Unresectable or metastatic melanoma: Dabrafenib is mainly used to treat patients with unresectable or metastatic melanoma who have BRAF V600E mutation. Such patients usually face greater treatment challenges, and targeted drugs can precisely target cancer cells and improve efficacy.

(1)Combined use: When used in combination with trametinib, it can be used to treat unresectable or metastatic melanoma with BRAF V600E or V600K mutations. Combination treatment regimens often enhance effectiveness and improve patient survival.

(2)Adjuvant therapy: For patients with BRAF V600E or V600K mutation melanoma whose lymph nodes are still involved after complete resection, dabrafenib can be used as adjuvant therapy to reduce the risk of recurrence and further improve the cure rate.

2. Metastatic non-small cell lung cancer: Dabrafenib can also be used to treat metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutations, providing a new treatment option for this complex cancer.

3. Anaplastic thyroid cancer: In the absence of satisfactory local treatment options, dabrafenib can be used to treat locally advanced or metastatic anaplastic thyroid cancer with BRAF V600E gene mutations.

4. Solid tumors in adults and children: Dabrafenib is suitable for patients with unresectable or metastatic BRAF V600E mutated solid tumors, including adults and children aged 6 years and above. These patients have disease progression on prior therapy and lack satisfactory alternative treatment options.

5, Low-grade glioma

In addition, the drug can treat patients with BRAF V600E-mutated low-grade glioma (LGG) aged 1 year and older, particularly those children who require systemic therapy.

2. Use restrictions

Dabrafenib is not indicated for the treatment of patients with wild-type BRAF melanoma, wild-type BRAF NSCLC, or wild-type BRAF anaplastic thyroid cancer. Therefore, patients must undergo genetic testing to confirm BRAF gene status before starting treatment.

3. Usage and dosage

The recommended dosage of dabrafenib is oral administration 150 mg twice daily. To ensure optimal absorption of the drug, patients are advised to take it at least one hour before or two hours after a meal. This usage helps avoid food interference on drug absorption and improves therapeutic effect.

4. Precautions

1. Monitor side effects: While using dabrafenib, patients should undergo regular follow-up examinations to monitor possible side effects, such as rash, fever, fatigue, etc. If serious side effects occur, you should report it to your doctor in time and adjust your medication according to your doctor's advice.

2. Follow medical advice: During the medication period, patients should strictly follow the doctor's medication recommendations and regular inspections so that dosage adjustments or dressing changes can be made when necessary.

3. Avoid combined use with specific drugs: When using dabrafenib, patients should inform their doctors about other drugs they are taking to avoid drug interactions.

Reference materials:https://go.drugbank.com/drugs/DB08912